Early hemostatic disorders in patients with gynecologic tumors.
One hundred and seventeen female subjects were studied: 23 patients with cervical carcinoma; 25 with endometrial carcinoma; 29 with benign uterine diseases; 14 with ovarian carcinoma; 26 patients with benign ovarian tumors. These patients, together with 25 healthy female control subjects, underwent several coagulation tests including Beta-Thromboglobulin (Beta-TG) and Platelet Factor 4 (PF4) plasma levels. Among all Beta-TG and PF4 exhibited the most interesting results. They were increased in four groups of patients: those with malignant 92.2% (13/14) and benign 50% (13/26) ovarian tumors and those with endometrial 64% (16/25) and cervical carcinoma 69.5% (16/23). Our study showed a high incidence of abnormalities of Beta-TG and PF4, early signs of hemostatic disorders, in gynecological malignancies especially in ovarian carcinoma. These data suggest a possible value of these tests as tumor-markers and in order to detect the patients who develop thrombo-embolic accidents.
D000328:Adult; D000347:Afibrinogenemia / Q000175:diagnosis / Q000209:etiology; D001778:Blood Coagulation Disorders / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005833:Genital Neoplasms, Female / Q000097:blood / Q000150:complications* / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood; D010978:Platelet Factor 4 / Q000378:metabolism; D002583:Uterine Cervical Neoplasms / Q000097:blood; D014594:Uterine Neoplasms / Q000097:blood; D001620:beta-Thromboglobulin / Q000378:metabolism
D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D005340:Fibrinogen